Natera, Inc. $NTRA Shares Acquired by Arrowstreet Capital Limited Partnership

Arrowstreet Capital Limited Partnership grew its holdings in Natera, Inc. (NASDAQ:NTRA) by 111.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,179,939 shares of the medical research company’s stock after purchasing an additional 620,954 shares during the quarter. Arrowstreet Capital Limited Partnership’s holdings in Natera were worth $270,312,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Palladiem LLC acquired a new stake in Natera during the fourth quarter worth approximately $31,000. Horizon Investments LLC purchased a new position in shares of Natera in the 3rd quarter valued at $32,000. Bank of Jackson Hole Trust raised its stake in shares of Natera by 103.8% in the 4th quarter. Bank of Jackson Hole Trust now owns 163 shares of the medical research company’s stock valued at $37,000 after acquiring an additional 83 shares during the period. Flagship Harbor Advisors LLC purchased a new position in shares of Natera in the 4th quarter valued at $41,000. Finally, Greenline Wealth Management LLC purchased a new position in shares of Natera in the 4th quarter valued at $41,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Natera Stock Performance

Shares of NTRA opened at $212.07 on Monday. The business’s 50-day moving average price is $206.49 and its 200 day moving average price is $215.83. The stock has a market capitalization of $30.37 billion, a P/E ratio of -130.10 and a beta of 1.56. Natera, Inc. has a 1-year low of $131.81 and a 1-year high of $256.36.

Analysts Set New Price Targets

NTRA has been the topic of several analyst reports. Evercore reaffirmed an “outperform” rating and set a $270.00 price target on shares of Natera in a research note on Friday, May 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Natera in a report on Tuesday, April 21st. Piper Sandler reaffirmed an “overweight” rating and issued a $249.00 price target on shares of Natera in a report on Tuesday, May 12th. Wolfe Research assumed coverage on shares of Natera in a research note on Tuesday, June 2nd. They set an “outperform” rating and a $260.00 target price for the company. Finally, JPMorgan Chase & Co. upped their price target on shares of Natera from $260.00 to $265.00 and gave the stock an “overweight” rating in a research note on Friday, May 8th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $256.53.

Insider Activity at Natera

In other news, insider John Fesko sold 1,438 shares of the stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $202.84, for a total value of $291,683.92. Following the completion of the sale, the insider owned 185,782 shares in the company, valued at $37,684,020.88. This represents a 0.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Roelof Botha sold 78,000 shares of the company’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $220.31, for a total value of $17,184,180.00. Following the transaction, the director directly owned 1,076,198 shares in the company, valued at $237,097,181.38. The trade was a 6.76% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 159,378 shares of company stock worth $34,640,860. Insiders own 5.05% of the company’s stock.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.